FDA Accepts for Review Merck’s Biologics License Application for V503, Investigational 9-valent Human Papillomavirus Vaccine

21-02-2014 Business Wire HealthComments (0)

Merck & CoUSA

Merck announced today that the Biologics License Application for V503, its investigational 9-valent human papillomavirus vaccine, has been accepted for standard review by the U.S. FDA.

Read more on Business Wire Health

Your Comments

Login to add a comment

There are no comments yet. Be the first and leave a response!

Back to top